The dual IGF-1R/IR blocker, Linsitinib, modulates human orbital fibroblast activity and proliferation
Open Access
- 2 October 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1920590
Abstract
Aim: The insulin-like growth factor-1 receptor (IGF-1R) and its downstream signaling pathways drive proliferation, survival, and extracellular matrix production, representing key therapeutic targets in thyroid eye disease (TED). This novel in vitro study investigated the inhibitory effects of the dual IGF-1R/insulin receptor small-molecule inhibitor Linsitinib on orbital target cell activity, proliferation, and survival. Methods: Human orbital fibroblasts (OF) were pre-treated with increasing doses of Linsitinib and stimulated with 100 ng/mL IGF-1 to quantify hyaluronic acid (HA) and pro-collagen in supernatants via ELISA. Intracellular protein kinase B (AKT) phosphorylation at Serine 473 was quantified in cell lysates. Additionally, an equimolar comparison between Linsitinib and the anti-IGF-1R monoclonal antibody Teprotumumab was performed in IGF-1R-expressing cells. Proliferation was assessed both microscopically and by tetrazolium assay, while apoptosis was evaluated by caspase-3/7 activity. Results: Linsitinib markedly suppressed IGF-1-induced HA and pro-collagen secretion, with TED OF showing significantly greater sensitivity and exclusive morphological evidence of apoptosis compared to control OF. Linsitinib effectively inhibited IGF-1-induced AKT phosphorylation to baseline levels in OF. Equimolar comparison in IGF-1R-expressing cells demonstrated that Linsitinib outperformed Teprotumumab in inhibiting cell proliferation across most tested concentrations, whereas Teprotumumab showed higher potency only at the lowest concentrations. While Teprotumumab failed to induce cell death, Linsitinib triggered robust activity of the apoptosis markers caspase-3/7. Morphologically, in contrast to Teprotumumab, Linsitinib induced dose-dependent changes characterized by cellular contraction and formation of gaps in the monolayer. Conclusion: Linsitinib reverses OF activation through intracellular kinase blockade while outperforming Teprotumumab in equimolar comparison. These findings highlight the role of Linsitinib as a potent, dual-targeted therapy for TED.Keywords
This publication has 67 references indexed in Scilit:
- The pharmacology and therapeutic applications of monoclonal antibodiesPharmacology Research & Perspectives, 2019
- AKT and ERK dual inhibitors: The way forward?Cancer Letters, 2019
- AKT signaling in ERBB2-amplified breast cancerPharmacology & Therapeutics, 2016
- The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumorsCancer Treatment Reviews, 2012
- Targeted Therapies for Adrenocortical Carcinoma: IGF and BeyondDiscover Oncology, 2011
- Dissecting the role of mTOR: Lessons from mTOR inhibitorsBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Structure and function of the type 1 insulin-like growth factor receptorCellular and Molecular Life Sciences, 2000
- Mechanism of activation of protein kinase B by insulin and IGF‐1.The EMBO Journal, 1996
- Insulin‐like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity.The EMBO Journal, 1986